CAPRO™ Platform
Patented polymer excipient · Release by design
MORE™ Platform
Patent-pending oral wafer · OTC + Rx
Long-Acting Injectables
SubQ · IM · IA · Biodegradable implant
Home › Company

Engineering better
therapeutics.
For every patient.

Trekka Therapeutics is a biomaterial platform company commercializing two proprietary biomaterial platforms — CAPRO™ and MORE™ — built to solve the formulation problems that keep promising molecules from reaching patients. Not as a single-asset biotech. As a platform company.

Company Structure
Trekka Therapeutics, Inc.
Biomaterial platform company — Saint Paul, MN · Est. 2018
Dual Platform Engine
CAPRO™
Patented injectable & oral depot
Cleavable linker polymer · zero burst · biologic-compatible · GMP ready
Patent granted
Pre-IND FDA ✓
MORE™
Patent-pending oral wafer
Fast-dissolve sublingual · OTC + Rx · ambient stable · no water needed
Patent pending
OTC & Rx programs
Who we are

A platform company — not a single-asset biotech.

Trekka was founded on a single conviction: the formulation problems limiting most drugs are solvable — and solving them systematically with the right platform technology creates compounding value for patients, partners, and the company.

Mission
Improve how drugs are delivered — for better outcomes and broader access.
The gap between what a drug can do and what a patient actually receives is a formulation problem. Every Trekka program — whether proprietary or partnered — is designed to close that gap for a specific molecule and the patients who need it.
Vision
Platforms, not products. A platform that works for one API works for many.
Every successful program validates CAPRO™ and MORE™ more broadly — creating compounding scientific and commercial value that a single-product bet cannot replicate. The platform is the asset.
Approach
Science first. 505(b)(2) strategy built in from the very first evaluation.
Trekka doesn't separate scientific rigor from commercial strategy. Every formulation program is designed for 505(b)(2) from the first molecule evaluation — regulatory strategy is the foundation, not an afterthought.
What makes Trekka different

Four structural advantages no single competitor has all of.

These aren't positioning claims — they are architectural features of how the company, its platforms, and its commercialization model are built.

Two platforms — not one
CAPRO™ and MORE™ address different problems and combine to unlock molecules neither can deliver alone. No other drug delivery company has both.
CAPRO™ + MORE™
Dual revenue from day one
Proprietary drug programs and platform licensing run simultaneously. MORE™ OTC generates near-term revenue that funds CAPRO™ Rx development — no single-asset dependence.
Self-funding model
505(b)(2) & GMP built in
Every Rx program is designed for 505(b)(2) from evaluation. GMP processes are developed in-house today. Partners don't wait for manufacturing buildout — it's ready.
Regulatory-first
Granted patent — advancing through pre-clinical
CAPRO™ is a granted patent and MORE™ is patent-pending — the IP foundation is secure. CAPRO™ is currently in pre-clinical development; GMP manufacturing processes are being developed in parallel, ready to scale once clinical approval is obtained.
Strong IP foundation
Our story

Built from the ground up to solve what legacy platforms can't.

Trekka started with a fundamental observation — most drugs fail to reach their full potential not because of pharmacology, but because of delivery. CAPRO™ and MORE™ were built from the ground up to fix that.

The problem
40% of marketed drugs. 90% of the pipeline. All limited by delivery — not pharmacology.
Poor solubility, instability, short half-life, uncontrolled release. Legacy excipient technology — largely unchanged for decades — wasn't solving them. CAPRO™ and MORE™ were designed from the ground up to.
The science
A new polymer architecture — cleavable linkers that pre-program release at the molecular level.
Developed by Dr. Chun Wang, PhD. Functional polymer blocks + cleavable linkers eliminate burst release and acidic byproducts — the two defining limitations of PLGA.
The company
Founded 2018. Two platforms. Two revenue paths. One compounding system.
Trekka commercializes CAPRO™ and MORE™ through proprietary drug programs and platform licensing — simultaneously. MORE™ OTC generates near-term revenue while CAPRO™ Rx programs advance. Pre-IND FDA engagement complete. GMP validated.
Current pipeline
Program
Platform
Indication
Stage
Path
Melanoma Cancer Vaccine
CAPRO™ SubQ LAI · Pre-IND
CAPRO™
Oncology / Immunology
Pre-IND
NDA
LAI Pain Depot
Depot reformulation of approved analgesic
CAPRO™
Pain / Analgesia
Preclinical
505(b)(2)
Intra-oral Pain
MORE™ fast-dissolve sublingual wafer
MORE™
Pain / Consumer
Development
RxOTC
Biologic LAI — Partner
Long-acting injectable for approved biologic
CAPRO™
Autoimmune / Oncology
Evaluation
505(b)(2)
Partner programs subject to confidentiality. Additional programs under evaluation.
Leadership

The team behind the science and the strategy.

Trekka's leadership combines deep polymer science expertise and pharmaceutical development experience — built specifically to translate platform technology from lab to commercial product.

BW
Bob Wieden
President & CEO
Trekka Therapeutics, Inc.
Commercial strategy Business development Platform licensing Investor relations Corporate operations Strategic partnerships
CW
Chun Wang, PhD
Chief Scientific Officer, Trekka Therapeutics, Inc.
Associate Professor, Dept. of Biomedical Engineering — University of Minnesota
Polymer chemistry Formulation science Controlled release Biologic delivery GMP development CAPRO™ inventor
Scientific Advisory Board

World-class expertise in medicinal chemistry, oncology, and drug delivery.

Trekka's scientific advisors bring specialized expertise directly critical to the platform programs — guiding CAPRO™ formulation chemistry decisions, API class compatibility, and the oncology clinical strategy.

VG
Vadim Gurvich, PhD, MBA
Drug Discovery & Medicinal Chemistry
Dept. of Medicinal Chemistry & Chemical Process Development (ITDD)
University of Minnesota
MB
Dr. Matthew Block, MD, PhD
Oncology Immunology
Department of Oncology
Mayo Clinic
Trekka's scientific advisory board is structured to provide expertise directly relevant to current platform programs — medicinal chemistry and API compatibility for CAPRO™ partnership evaluation, and clinical oncology guidance for the Mayo Clinic melanoma vaccine program. Additional advisors are engaged as specific platform applications and therapeutic areas expand.
Ready to build something
with Trekka?
Proprietary programs · Platform licensing · Co-development · Custom formulation. Whether you have a molecule with a formulation challenge or a product category that deserves a better delivery format — we'd like to talk. All inquiries treated confidentially.